|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:age
|
9 to 45 years
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
2015
|
|
gptkbp:ATCCode
|
J07BX17
|
|
gptkbp:brand
|
gptkb:Dengvaxia
|
|
gptkbp:composition
|
recombinant, chimeric virus
|
|
gptkbp:contraindication
|
seronegative individuals
|
|
gptkbp:developedBy
|
gptkb:Sanofi_Pasteur
|
|
gptkbp:doseInterval
|
6 months
|
|
gptkbp:firstApprovedCountry
|
gptkb:Mexico
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dengvaxia
|
|
gptkbp:indication
|
prevention of dengue
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Pasteur
|
|
gptkbp:marketedIn
|
gptkb:Brazil
gptkb:El_Salvador
gptkb:Mexico
gptkb:Paraguay
gptkb:Philippines
gptkb:Singapore
|
|
gptkbp:numberOfDoses
|
3
|
|
gptkbp:regulates
|
controversy in the Philippines
|
|
gptkbp:riskFactor
|
severe dengue in seronegative individuals
|
|
gptkbp:routeOfAdministration
|
injection
|
|
gptkbp:sideEffect
|
fever
headache
muscle pain
injection site pain
allergic reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:targetsSerotypes
|
gptkb:DENV-1
gptkb:DENV-2
gptkb:DENV-3
gptkb:DENV-4
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:usedFor
|
dengue fever
|
|
gptkbp:WHOPrequalification
|
2016
|
|
gptkbp:bfsParent
|
gptkb:Dengue_Fever
|
|
gptkbp:bfsLayer
|
5
|